Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
I
116TH CONGRESS
2D SESSION
H. R. 7650
To require the Director of U.S. Immigration and Customs Enforcement
to ensure that foreign nationals test negative for SARS–CoV–2 before
repatriation or removal, and for other purposes.
IN THE HOUSE OF REPRESENTATIVES
JULY 16, 2020
Mr. NADLER (for himself, Ms. LOFGREN, Mr. CA´RDENAS, Mr. CORREA, Ms.
DEAN, Mrs. DEMINGS, Mr. DEUTCH, Ms. GARCIA of Texas, Mrs. HAYES,
Ms. JACKSON LEE, Mr. JOHNSON of Georgia, Mr. TED LIEU of Cali-
fornia, Ms. NORTON, Mr. PANETTA, Mr. RASKIN, Ms. SCANLON, Mr.
VARGAS, and Ms. VELA´ZQUEZ) introduced the following bill; which was
referred to the Committee on the Judiciary
A BILL
To require the Director of U.S. Immigration and Customs
Enforcement to ensure that foreign nationals test nega-
tive for SARS–CoV–2 before repatriation or removal,
and for other purposes.
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled,
2
SECTION 1. SHORT TITLE.
3
This Act may be cited as the ‘‘Coronavirus Contain-
4
ment Act of 2020’’.
5
VerDate Sep 11 2014
05:02 Aug 07, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7650.IH
H7650
pbinns on DSKJLVW7X2PROD with BILLS
2
•HR 7650 IH
SEC. 2. FINDINGS.
1
Congress finds the following:
2
(1) U.S. Immigration and Customs Enforce-
3
ment repatriated or attempted to repatriate dozens
4
of foreign nationals who tested positive for SARS–
5
CoV–2 prior to departure from the United States or
6
upon arrival in their country of destination.
7
(2) Haiti is one of the most vulnerable nations
8
in the world to SARS–CoV–2 with only a few dozen
9
ventilators for 11 million people. Yet, in April 2020,
10
multiple individuals who were repatriated or other-
11
wise removed to Haiti on a single flight tested posi-
12
tive for SARS–CoV–2 upon their arrival. In May,
13
U.S.
Immigration
and
Customs
Enforcement
14
planned to repatriate more than 100 individuals to
15
Haiti, including individuals known to have COVID–
16
19, but abandoned these plans after media scrutiny
17
and pressure from the Haitian government.
18
(3) As of mid-May 2020, more than 100 indi-
19
viduals have tested positive for SARS–CoV–2 upon
20
arrival in Guatemala, prompting Guatemala to sus-
21
pend repatriation flights from the United States on
22
several occasions.
23
(4) U.S. Immigration and Customs Enforce-
24
ment’s patchwork approach to the screening and
25
testing of deportees prior to repatriation has failed,
26
VerDate Sep 11 2014
05:02 Aug 07, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7650.IH
H7650
pbinns on DSKJLVW7X2PROD with BILLS
3
•HR 7650 IH
leading to the removal of dozens of individuals in-
1
fected with SARS–CoV–2 to countries with over-
2
taxed healthcare infrastructures, furthering the glob-
3
al spread of the disease.
4
SEC. 3. TESTING BEFORE REPATRIATION OR REMOVAL.
5
(a) IN GENERAL.—During the period described in
6
subsection (c), the Director of U.S. Immigration and Cus-
7
toms Enforcement shall, prior to the repatriation or re-
8
moval of any individual—
9
(1) conduct a viral test to determine if such an
10
individual is infected with SARS–CoV–2; and
11
(2) engage with the receiving country to ensure,
12
subject to subsection (b), that such an individual can
13
be safely removed or otherwise repatriated.
14
(b) LIMITATION ON REPATRIATION OR REMOVAL.—
15
In the case that an individual tested under subsection
16
(a)(1) tests positive for SARS–CoV–2, such individual
17
may not be removed or otherwise repatriated until such
18
individual—
19
(1) exhibits no symptoms of COVID–19 for at
20
least 10 days; and
21
(2) is administered 2 additional viral tests more
22
than 24 hours apart and tests negative for SARS–
23
CoV–2 each time such a viral test is administered.
24
VerDate Sep 11 2014
05:02 Aug 07, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7650.IH
H7650
pbinns on DSKJLVW7X2PROD with BILLS
4
•HR 7650 IH
(c) PERIOD DESCRIBED.—The period described in
1
this section is the period beginning on the date of the en-
2
actment of this Act and ending 180 days after the date
3
on which the public health emergency declared by the Sec-
4
retary of Health and Human Services under section 319
5
of the Public Health Service Act (42 U.S.C. 247d) with
6
respect to COVID–19 is terminated.
7
SEC. 4. REPORTING REQUIREMENTS.
8
Not later than 60 days after the date of the enact-
9
ment of this Act, the Director of U.S. Immigration and
10
Customs Enforcement shall publish on its public website,
11
and update on a weekly basis, information related to test-
12
ing of individuals it intends to remove or repatriate. Such
13
information shall be delineated by facility and shall in-
14
clude—
15
(1) the number of removals and repatriations,
16
delineated by country of origin;
17
(2) the results of the viral tests administered to
18
individuals U.S. Immigration and Customs Enforce-
19
ment intends to remove or repatriate; and
20
(3) in the case of individuals U.S. Immigration
21
and Customs Enforcement intends to remove or re-
22
patriate who test positive for SARS–CoV–2, the av-
23
erage length of stay in detention for such individ-
24
uals.
25
VerDate Sep 11 2014
05:02 Aug 07, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7650.IH
H7650
pbinns on DSKJLVW7X2PROD with BILLS
5
•HR 7650 IH
SEC. 5. DEFINITIONS.
1
In this Act:
2
(1)
SYMPTOMS
OF
COVID–19.—The
term
3
‘‘symptoms of COVID–19’’ includes—
4
(A) fever or chills;
5
(B) cough;
6
(C) shortness of breath or difficulty
7
breathing;
8
(D) fatigue;
9
(E) muscle or body aches;
10
(F) headaches;
11
(G) new loss of taste or smell;
12
(H) sore throat;
13
(I) congestion or runny nose;
14
(J) nausea or vomiting;
15
(K) diarrhea; or
16
(L) any other symptom that the Director
17
of the Centers for Disease Control and Preven-
18
tion determines to be a symptom of COVID–19.
19
(2) VIRAL TEST.—The term ‘‘viral test’’ means
20
a diagnostic test with respect to SARS–CoV–2 that
21
is approved, cleared, or authorized under section
22
510(k), 513, 515 or 564 of the Federal Food, Drug,
23
and Cosmetic Act (21 U.S.C. 360(k), 360c, 360e, or
24
360bbb–3).
25
Æ
VerDate Sep 11 2014
05:02 Aug 07, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H7650.IH
H7650
pbinns on DSKJLVW7X2PROD with BILLS
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.